Pacira’s Long Day With Exparel
Many an unfortunate NDA sponsor has faced a long day when heading into US FDA advisory committee review. But Pacira faced a really long day for the review of a supplemental indication of Exparel. In fact, it was a day and a half.
You may also be interested in...
In unusual move, labeling lists data supporting use as nerve block as well as other trials that 'do not support' a broader nerve block indication beyond brachial plexus; labeling includes data on reduced opioid use but notes clinical benefit has not been established.
Inconsistent efficacy data and safety concerns about falls and systemic toxicity lead to advisory committee vote against a labeling expansion for the local anesthetic; Pacira's proposed revisions to the drug's existing infiltration claim also meet some resistance.
Many of the advisory panel members felt the company's proposed buy-back program could not be feasible in practice.